The result was nearly seven figures of new recurring revenue for Vertex across a comprehensive solution set including sales, ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential.

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a ...

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

Hello and thanks for joining us to discuss Vertex Inc third quarter financial results. I'm Joe Crivelli, Vice President, Investor Relations, David DiStefano, our President and CEO and John Schwab. Our ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...